Advertisement

Topics

Illumina Grows Clinical IVD Portfolio with Introduction of NextSeq™ 550Dx System and Expanded Use of MiSeq™Dx System

09:00 EST 15 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Systems, reagents and software to cover broad range of clinical applications Illumina, Inc. (NASDAQ: ILMN) announced today the introduction of its NextSeq™ 550Dx instrument, the company’s second FDA-regulated and CE-IVD ...

Other Sources for this Article

Illumina, Inc.
Investors:
Jacquie Ross, CFA
858-255-5243
IR@illumina.com
or
Media:
Tina Amirkiai
858-882-6822
PR@illumina.com

NEXT ARTICLE

More From BioPortfolio on "Illumina Grows Clinical IVD Portfolio with Introduction of NextSeq™ 550Dx System and Expanded Use of MiSeq™Dx System"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

DNA sequencing
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...